MX2009004053A - 1,5-difenil-3-piridinilamino-1,5-dihidropirrolidin-2-ona como modulador de receptor de cb1. - Google Patents

1,5-difenil-3-piridinilamino-1,5-dihidropirrolidin-2-ona como modulador de receptor de cb1.

Info

Publication number
MX2009004053A
MX2009004053A MX2009004053A MX2009004053A MX2009004053A MX 2009004053 A MX2009004053 A MX 2009004053A MX 2009004053 A MX2009004053 A MX 2009004053A MX 2009004053 A MX2009004053 A MX 2009004053A MX 2009004053 A MX2009004053 A MX 2009004053A
Authority
MX
Mexico
Prior art keywords
forumla
antipsychotics
blockade
schizophrenia
mammals
Prior art date
Application number
MX2009004053A
Other languages
English (en)
Spanish (es)
Inventor
Perry Clark Heath
John Mehnert Schaus
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2009004053A publication Critical patent/MX2009004053A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2009004053A 2006-10-23 2007-10-22 1,5-difenil-3-piridinilamino-1,5-dihidropirrolidin-2-ona como modulador de receptor de cb1. MX2009004053A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86254006P 2006-10-23 2006-10-23
PCT/US2007/082041 WO2008070305A2 (en) 2006-10-23 2007-10-22 1, 5-diphenyl-3-pyridinylamino-1, 5-dihydropyrrolidin-2-one as cbl' receptor modulator

Publications (1)

Publication Number Publication Date
MX2009004053A true MX2009004053A (es) 2009-04-27

Family

ID=39386481

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009004053A MX2009004053A (es) 2006-10-23 2007-10-22 1,5-difenil-3-piridinilamino-1,5-dihidropirrolidin-2-ona como modulador de receptor de cb1.
MX2009004054A MX2009004054A (es) 2006-10-23 2007-10-22 1,5-difenil-3-bencilamino-1,5-dihidropirrolidin-2-ona como moduladores de receptor de cb1.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2009004054A MX2009004054A (es) 2006-10-23 2007-10-22 1,5-difenil-3-bencilamino-1,5-dihidropirrolidin-2-ona como moduladores de receptor de cb1.

Country Status (23)

Country Link
US (2) US8168659B2 (https=)
EP (2) EP2099784B1 (https=)
JP (2) JP5331002B2 (https=)
KR (2) KR101088229B1 (https=)
CN (2) CN101528733B (https=)
AR (1) AR063497A1 (https=)
AT (1) ATE492543T1 (https=)
AU (1) AU2007329808B2 (https=)
BR (1) BRPI0717347A2 (https=)
CA (2) CA2667372C (https=)
CL (1) CL2007003002A1 (https=)
CY (1) CY1111140T1 (https=)
DE (1) DE602007011495D1 (https=)
DK (2) DK2094684T3 (https=)
EA (2) EA015175B1 (https=)
ES (2) ES2356025T3 (https=)
MX (2) MX2009004053A (https=)
PE (1) PE20080926A1 (https=)
PL (2) PL2094684T3 (https=)
PT (2) PT2099784E (https=)
SI (2) SI2094684T1 (https=)
TW (1) TW200825067A (https=)
WO (2) WO2008070305A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825067A (en) * 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds
SI2280961T1 (sl) * 2008-04-22 2012-11-30 Lilly Co Eli Spojine difenil pirolidin ona kot ligandi cb
EA201071222A1 (ru) 2008-04-22 2011-12-30 Эли Лилли Энд Компани Соединения 1,5-дифенилпирролидин-2-она в качестве лигандов cb-1
US20110280813A1 (en) * 2008-11-13 2011-11-17 Alice Prince Neuraminidase inhibitors and uses thereof
EP2593477A2 (en) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US20240158384A1 (en) * 2020-12-14 2024-05-16 The Board Of Trustees Of The Leland Stanford Junior University Cb2 receptor agonists
WO2023205180A1 (en) 2022-04-19 2023-10-26 Nurix Therapeutics, Inc. Biomarkers for cbl, and compositions and methods for their use
US20230414598A1 (en) 2022-06-22 2023-12-28 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds and antiemetic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
HRP20080689T3 (hr) * 2004-02-19 2009-05-31 Solvay Pharmaceuticals B.V. Imidazolinski derivati sa cb1-antagonističkom aktivnosti
US20060035245A1 (en) * 2004-04-20 2006-02-16 Ason Brandon L Modulators of enzymatic nucleic acid elements mobilization
WO2007020502A2 (en) 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Cannabinoid receptor ligands and uses thereof
TW200825067A (en) * 2006-10-23 2008-06-16 Lilly Co Eli CB1 compounds

Also Published As

Publication number Publication date
CA2667210A1 (en) 2008-06-12
EA015175B1 (ru) 2011-06-30
PL2094684T3 (pl) 2011-05-31
PE20080926A1 (es) 2008-07-19
ES2356025T3 (es) 2011-04-04
KR101088236B1 (ko) 2011-11-30
US7998985B2 (en) 2011-08-16
US20100016375A1 (en) 2010-01-21
AU2007329807A1 (en) 2008-06-12
EP2094684B1 (en) 2010-12-22
CA2667372A1 (en) 2008-06-12
WO2008070305A3 (en) 2008-08-28
WO2008070306A2 (en) 2008-06-12
MX2009004054A (es) 2009-04-27
EA015745B1 (ru) 2011-10-31
SI2094684T1 (sl) 2011-04-29
BRPI0717347A2 (pt) 2014-01-14
JP5331001B2 (ja) 2013-10-30
EA200970405A1 (ru) 2009-12-30
DK2094684T3 (da) 2011-03-14
CA2667372C (en) 2013-09-03
EP2099784B1 (en) 2012-12-12
EP2094684A2 (en) 2009-09-02
JP2010507589A (ja) 2010-03-11
US20090275618A1 (en) 2009-11-05
ATE492543T1 (de) 2011-01-15
US8168659B2 (en) 2012-05-01
CL2007003002A1 (es) 2008-06-06
PT2094684E (pt) 2011-01-28
KR20090069316A (ko) 2009-06-30
AU2007329808B2 (en) 2013-11-07
PT2099784E (pt) 2013-01-04
CN101528733A (zh) 2009-09-09
WO2008070306A3 (en) 2008-07-31
CY1111140T1 (el) 2015-06-11
EP2099784A2 (en) 2009-09-16
JP5331002B2 (ja) 2013-10-30
CN101528733B (zh) 2013-10-16
DE602007011495D1 (de) 2011-02-03
PL2099784T3 (pl) 2013-05-31
EA200970404A1 (ru) 2009-10-30
DK2099784T3 (da) 2013-01-14
CA2667210C (en) 2013-09-24
ES2398388T3 (es) 2013-03-15
KR20090071613A (ko) 2009-07-01
TW200825067A (en) 2008-06-16
AU2007329808A1 (en) 2008-06-12
SI2099784T1 (sl) 2013-02-28
JP2010507590A (ja) 2010-03-11
KR101088229B1 (ko) 2011-11-30
AR063497A1 (es) 2009-01-28
WO2008070305A2 (en) 2008-06-12
CN101528732A (zh) 2009-09-09
CN101528732B (zh) 2013-04-03

Similar Documents

Publication Publication Date Title
MX2009004053A (es) 1,5-difenil-3-piridinilamino-1,5-dihidropirrolidin-2-ona como modulador de receptor de cb1.
MX2010010407A (es) Derivados de 4-aminociclohexanos sustituidos.
CL2012000707A1 (es) Compuestos derivados de [5-(pirrolo[1,2-c][1.2.3]triazin-7-il)tetrahidrofuran-2-il]metanol; composición farmacéutica; y su uso para el tratamiento de la hepatitis c.
ME01532B (me) Jedinjenja
MY154909A (en) Novel thiophene derivatives
MX2009005252A (es) Aminopirrolidinas como antagonistas del receptor de quimiocina.
WO2007133802A3 (en) Pharmaceutical formulations of pimavanserin
TW200640867A (en) Pyridine-3-carboxamide derivatives as CB1 inverse agonists
MY181898A (en) Heterocyclic compounds and uses thereof
EP3542629A3 (en) Dithiol compounds, derivatives, and uses therefor
GB0812642D0 (en) Compounds
NZ591425A (en) Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases
IL192948A0 (en) Novel pyridine derivatives
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
MX2009003129A (es) Derivados de oxadiazol con propiedades anti-inflamatorias e inmunosupresoras.
MA29774B1 (fr) Utilisation de derives azabicyclo
WO2008113559A3 (en) Indolizines and aza-analog derivatives thereof as cns active compounds
IN2012DN02556A (https=)
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
TW200942535A (en) Novel compounds as cannabinoid receptor ligands
MX2012004264A (es) Derivados de sulfoxidos para el tratamiento de tumores.
ECSP11010801A (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
NZ606730A (en) Methods for treating antipsychotic-induced weight gain
WO2010012745A3 (en) Benzimidazoles

Legal Events

Date Code Title Description
FG Grant or registration